Vortioxetine Gydrobromide Tablets Uses

                                                                                       Vortioxetine Gydrobromide Tablets Uses

Vortioxetine Hydrobromide is a new type of bisarylsulfanylamine antidepressant jointly developed by Takeda Japan and Lingbei, Denmark. It is used in the treatment of depression and anxiety. In December 2013, the EMA European Commission granted vortioxetine the right to sell in the entire European Union. There are four specifications for vortioxetine: 5mg, 10mg, 15mg, 20mg. At present, vortioxetine hydrobromide has submitted listing applications in many countries, but has not been listed in my country.Vortioxetine hydrobromide is considered to be a new multi-model antidepressant drug. In vitro studies have shown that it can antagonize 5-HT3, 5-HT7 and 5-HT1D receptors, activate 5-HT1A receptors, and partially activate 5- HT1B receptor and inhibit 5-HT transport.

Valticetine hydrobromide is considered to be a novel multi-model antidepressant drug. In vitro studies have shown that it can antagonize 5-HT3, 5-HT7 and 5-HT1D receptors, activate 5-HT1A receptors, and partially activate 5- HT1B receptors and inhibit 5-HT transport.

Vortioxetine HBr
Lu AA21004 (HBr)
Lu AA 21004 hydrobromide
Vortioxetine hydrobromide
Vortioxetine (Lu AA21004) HBr
Vortioxetine (Lu AA21004) hydrobroMide
1-[2-[(2,4-Dimethylphenyl)thio]phenyl]piperazine hydrobromide
1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine hydrobromide
1-[2-(2,4-Dimethyl-phenylsulfanyl)-phenyl]-piperazine, hydrobromid
Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-, hydrobromide (1:1)